Synapse - Robert Motzer

Results (1243)

Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: Data from the phase III JAVELIN Renal 101 trial

Journal Article

Rini, B. I.; Moslehi, J. J.; Bonaca, M.; Schmidinger, M.; Albiges, L.; Choueiri, T. K.; Motzer, R. J.; Atkins, M. B.; Haanen, J.; Mariani, M.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial

Journal Article

Albiges, L.; Tannir, N. M.; Burotto, M.; McDermott, D.; Plimack, E. R.; Barthélémy, P.; Porta, C.; Powles, T.; Donskov, F.; George, S.; more...
European Urology (2022)

Fulltext@MSK | Save

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label, randomised, phase 3 trial

Journal Article

Motzer, R. J.; Powles, T.; Burotto, M.; Escudier, B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Hamzaj, A.; Porta, C.; Hocking, C. M.; more...
Lancet Oncology (2022)

Fulltext@MSK | Save

Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy

Journal Article

Carlo, M. I.; Attalla, K.; Mazaheri, Y.; Gupta, S.; Yildirim, O.; Murray, S. J.; Coskey, D. T.; Kotecha, R.; Lee, C. H.; Feldman, D. R.; more...
European Urology (2022)

Fulltext@MSK | Save

Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): A randomised, phase 3 study

Journal Article

Motzer, R.; Porta, C.; Alekseev, B.; Rha, S. Y.; Choueiri, T. K.; Mendez-Vidal, M. J.; Hong, S. H.; Kapoor, A.; Goh, J. C.; Eto, M.; more...
Lancet Oncology (2022)

Fulltext@MSK | Save

Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Journal Article

Motzer, R. J.; McDermott, D. F.; Escudier, B.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Barthélémy, P.; Plimack, E. R.; Porta, C.; George, S.; more...
Cancer (2022)

Fulltext@MSK | Save

Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting

Meeting Abstract

Shah, N. J.; Sura, S.; Shinde, R.; Shi, J.; Perini, R. F.; Puneet, S.; Robert, N. J.; Vogelzang, N. J.; Motzer, R. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Real-world clinical outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era

Meeting Abstract

Shah, N. J.; Sura, S.; Shinde, R.; Shi, J. X.; Perini, R. F.; Puneet, S.; Robert, N. J.; Vogelzang, N. J.; Motzer, R. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up

Meeting Abstract

Tannir, N. M.; Signoretti, S.; Choueiri, T. K.; McDermott, D. F.; Motzer, R. J.; George, S.; Powles, T.; Donskov, F.; Tykodi, S. S.; Pal, S. K.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma

Meeting Abstract

Powles, T.; Choueiri, T. K.; Burotto, M.; Escudier, B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Hamzaj, A.; Porta, C.; Hocking, C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save